Open Access

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

  • Joseph A Caruso1, 5, 7,
  • Cansu Karakas1, 2,
  • Jing Zhang2,
  • Min Yi3,
  • Constance Albarracin2,
  • Aysegul Sahin2,
  • Melissa Bondy4,
  • Jinsong Liu2, 5,
  • Kelly K. Hunt3 and
  • Khandan Keyomarsi1, 5, 6Email author
Breast Cancer Research201517:87

https://doi.org/10.1186/s13058-015-0572-5

Received: 15 April 2015

Accepted: 15 April 2015

Published: 25 June 2015

The original article was published in Breast Cancer Research 2014 16:3417

Erratum

During the editorial process preceding the publication of this article an error was introduced in the heading of “Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients.” This error was only noticed after publication of the final version. Specifically, both data-containing columns are labeled “Elafin Negative.” The data-containing column on the right should in fact be labeled “Elafin Positive (n = 482).” The corrected version can be found here (Table 1). Table 1 has also been updated in the original article to reflect the correct labeling of the columns.
Table 1

Univariate and multivariate analysis of elafin-positive cells in breast cancer patients

A. Univariate analysis, breast cancer (n = 793)

Factors

Elafin negative (n = 311)

Elafin positive (n = 482)

p-value

Age of diagnosis, year

  

0.02

  Mean

55.5

53.5

 

  Median (range)

55 (26–86)

52 (25–87)

 

Stage

  

<0.0001

  I

120 (38.7)

115 (24.0)

 

  IIA

128 (41.3)

241 (50.2)

 

  IIB

62 (20.0)

124 (25.8)

 

  Unknown

1

2

 

ER

  

<0.0001

  Positive

266 (85.5)

280 (58.3)

 

  Negative

45 (14.5)

200 (41.7)

 

  Unknown

0

2

 

PR

  

<0.0001

  Positive

218 (70.1)

236 (49.2)

 

  Negative

93 (29.9)

244 (50.8)

 

  Unknown

0

2

 

HER-2

  

0.013

  Positive

42 (13.5)

98 (20.4)

 

  Negative

269 (86.5)

383 (79.6)

 

  Unknown

0

1

 

Grade

  

<0.0001

  I

41 (14.2)

31 (6.8)

 

  II

186 (64.6)

197 (43.5)

 

  III

61 (21.2)

225 (49.7)

 

  Unknown

23

29

 

Tumor subtype

  

<0.0001

  Luminal A

185 (61.9)

158 (33.1)

 

  Luminal B

45 (15.1)

94 (19.8)

 

  Her2 positive

42 (14.0)

98 (20.7)

 

  Triple negative

27 (9.0)

125 (26.4)

 

  Unknown

12

7

 

Recurrence

  

<0.0001

  No

250 (80.9)

298 (62.3)

 

  Yes

59 (19.1)

180 (37.7)

 

  Unknown

2

4

 

B. Multivariate Cox proportional hazards analysis of clinicopathologic variables’ influence on breast cancer RFS in whole cohort (n = 793)

Factor

HR

Se

P

95% CI

Stage

    

  I

referent

   

  IIA

1.67

0.31

0.005

1.17-2.39

  IIB

2.41

0.47

<0.0001

1.65-3.52

Age

0.98

0.01

<0.0001

0.97-0.99

Elafin Positive

1.94

0.3

<0.0001

1.44-2.62

Notes

Authors’ Affiliations

(1)
Department of Experimental Radiation Oncology, University of Texas at MD Anderson Cancer Center
(2)
Department of Pathology, University of Texas at MD Anderson Cancer Center
(3)
Department of Surgical Oncology, University of Texas at MD Anderson Cancer Center
(4)
Baylor College of Medicine, Dan L. Duncan Cancer Center
(5)
The University of Texas Graduate School of Biomedical Sciences
(6)
Department of Experimental Oncology, UT, M.D. Anderson Cancer Center
(7)
Department of Pathology, UC San Francisco

References

  1. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, et al. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Canc Res. 2014;16:3417.View ArticleGoogle Scholar

Copyright

© Caruso et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement